Sector: MedicalMYRX (NASDAQ: MYRX)
Headlines
- Myriad Pharmaceuticals Inc. to Present at the 21st Annual Piper Jaffray Health Care Conference
Nov 23, 2009 09:52 PM | PJC
- Myriad Pharmaceuticals' Azixa(TM) is Efficacious in a Model of Human Brain Cancer and Its Activity is Additive With Avastin(R)
Oct 23, 2009 02:31 PM |
- Myriad Pharmaceuticals Announces the Identification of an IND Candidate for the Treatment of Cancer, Obesity, and Diabetes
Oct 13, 2009 04:22 PM |
- Griffin Securities Announces Investment Opinion on Targeting Cancer Stem Cells
Oct 09, 2009 09:11 AM | BMY, CRIS, EXEL, INFI, KERX
- Myriad Pharmaceuticals Elects Timothy R. Franson, M.D. to Its Board of Directors
Sep 15, 2009 08:03 AM | LLY
- Myriad Pharmaceutical's Tablet Formulation of MPC-4326 Reduces Viral Load in HIV-1 Patients
Sep 14, 2009 02:42 PM |
- Myriad Pharmaceuticals Announces Two Abstracts Selected for Presentation At 2009 ICAAC Annual Meeting
Sep 10, 2009 06:01 PM |
- 3 Stocks For Any Portfolio: PG, MYRX, SWY
Sep 06, 2009 11:46 AM | PG, SWY
- Myriad Pharmaceuticals, Inc. to Present At Upcoming Investor Conferences
Sep 03, 2009 06:01 PM | UBS
- FDA Calendar Updates: ACUR, KG, MYRX, NEPH, Eisai
Jul 02, 2009 03:45 PM | ACUR
- Form 4/A Laslie W Wayne For: Sep 10 (10K)
Sep 14, 2009 11:16 PM
- Form 4/A Berry Barbara For: Sep 10 (10K)
Sep 14, 2009 11:14 PM
- Form 4/A LOLLINI ROBERT J For: Sep 10 (10K)
Sep 14, 2009 11:14 PM
- Form 4/A Gibbs Andrew For: Sep 10 (10K)
Sep 14, 2009 11:14 PM
- Form 4/A Swabb Edward For: Sep 10 (10K)
Sep 14, 2009 11:14 PM
- Form 4/A HOBDEN ADRIAN N For: Sep 10 (10K)
Sep 14, 2009 11:08 PM
- Form 4 HOBDEN ADRIAN N For: Sep 10 (10K)
Sep 14, 2009 06:01 PM
- Form 4 Swabb Edward For: Sep 10 (10K)
Sep 14, 2009 06:01 PM
- Form 4 Gibbs Andrew For: Sep 10 (10K)
Sep 14, 2009 06:01 PM
- Form 4 LOLLINI ROBERT J For: Sep 10 (10K)
Sep 14, 2009 06:00 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
MYRX
|
Compare to S&P
|
| YTD |
-0.01 %
|
-0.01 %
|
| 4 Weeks |
-15.26 %
|
-16.18 %
|
| 12 Weeks |
16.38 %
|
9.72 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -0.01 %
|
|
EPS Growth in Last Year: -0.01 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
